newsfilter
← Latest News
Business Wire·

Catabasis Pharmaceuticals to Present Edasalonexent at the XVIII International Conference on Duchenne and Becker Muscular Dystrophy

BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, today announced that it will present the edasalonexent program in Phase 3 development for the treatment of Duchenne muscular dystrophy at the XVIII International Conference on Duchenne and Becker Muscular Dystrophy, organized by Parent Project, in Rome, Italy.